Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 1Phase 1/2 1

Status

Terminated 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Head & Neck 3Genitourinary 1Gastrointestinal 1

Conditions

Endometrial Neoplasms 7Ovarian Neoplasms 6Neoplasms 6Uterine Cervical Neoplasms 5Squamous Cell Carcinoma of Head and Neck 3Rectal Neoplasms 3Pancreatic Neoplasms 3Neoplasm Metastasis 3Head and Neck Neoplasms 3Colonic Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Breast Neoplasms 3Triple Negative Breast Neoplasms 2Lung Neoplasms 2Fallopian Tube Neoplasms 2Carcinoma, Neuroendocrine 2Vulvar Neoplasms 1Vaginal Neoplasms 1Turcot syndrome 1Small Cell Lung Carcinoma 1Sarcoma, Clear Cell 1Sarcoma 1Recurrence 1Penile Neoplasms 1Pathologic Complete Response 1Neoplasms, Second Primary 1Mesothelioma, Malignant 1Mesothelioma 1Melanoma 1MMRd/MSI-H Stage II-III Endometrial Cancer 1

Interventions

Cisplatin 131Cetuximab 80Radiotherapy 76Docetaxel 59Carboplatin 46pembrolizumab 45Paclitaxel 44Fluorouracil 42Radiotherapy, Intensity-Modulated 35Drug Therapy 17Radiation 14Nivolumab 14Gefitinib 14Gemcitabine 13Surgical Procedures, Operative 12Oxaliplatin 11Erlotinib Hydrochloride 11130-nm albumin-bound paclitaxel 11Pemetrexed 10Celecoxib 10Capecitabine 10Bevacizumab 10tislelizumab 9Filgrastim 9Amifostine 9Albumin-Bound Paclitaxel 9durvalumab 7atezolizumab 7Chemoradiotherapy 7toripalimab 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Head and Neck Neoplasms × dostarlimab × Clear all
NCT06062420 2026-05-22

A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck- GALAXIES H&N-202

GlaxoSmithKline

Phase 2 Active not recruiting
316 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT04313504 2026-05-07

Study Evaluating the Efficacy of Niraparib and Dostarlimab (TSR-042) in Recurrent/Metastatic HNSCC

University of Cincinnati

Phase 2 Completed
10 enrolled 9 charts
Head & Neck

Head and Neck Neoplasms

NCT04779151 2025-12-01

NIRADO

Gustave Roussy, Cancer Campus, Grand Paris

Phase 2 Terminated
51 enrolled
GastrointestinalGenitourinaryHead & Neck

Biliary Tract Neoplasms, Carcinoma, Renal Cell, Head and Neck Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡